CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
B 细胞成熟抗原靶向治疗在多发性骨髓瘤（MM）及复发/难治性 MM 中的临床进展（综述）
英文原题：Clinical updates of B‑cell maturation antigen‑targeted therapy in multiple myeloma (MM) and relapsed/refractory MM (Review).
查看英文原题
Clinical updates of B‑cell maturation antigen‑targeted therapy in multiple myeloma (MM) and relapsed/refractory MM (Review).
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
尽管近年来多发性骨髓瘤（MM）管理取得显著进展，仍有部分患者治疗应答持续时间较短，常在18个月内复发。这些患者通常具有高危遗传突变，且对现行疗法应答很少或无应答，凸显进一步探索MM最佳治疗靶点的必要性。B细胞成熟抗原（BCMA）在成熟B淋巴细胞和浆细胞中高度表达，在MM中上调，是有前景的治疗靶点。多种BCMA靶向策略，包括抗体药物偶联物、双特异性T细胞衔接器及CAR-T 细胞疗法，正在临床评估，以优化疗效和安全性。本综述总结这些策略的最新临床进展，重点介绍其治疗MM及复发/难治性MM的疗效，并提供克服当前挑战的未来展望和建议。
展开英文摘要原文
Despite significant progress in managing multiple myeloma (MM) in recent years, certain patients still have a short duration of therapeutic response, often relapsing within 18 months. These patients typically have high risk genetic mutations and may show little to no response to current treatments, highlighting the need for further exploration of optimal therapeutic targets for MM. B cell maturation antigen (BCMA), highly expressed in mature B lymphocytes and plasma cells and upregulated in MM, is a promising therapeutic target.
Various BCMA targeted strategies, including antibody drug conjugates, bispecific T cell engagers and chimeric antigen receptor T cell therapy, are under clinical evaluation to optimize efficacy and safety. This review summarizes the latest clinical updates on these strategies, highlights their effectiveness in MM and relapsed/refractory MM and provides future perspectives and recommendations for overcoming current challenges.
论文信息
- 作者
- Xing R、Wang M、Wang L、Pan M、Wang Y、Zhou H
- 第一作者单位
- Department of Hematology, Dongyang Hospital Affiliated to Wenzhou Medical University, Dongyang People's Hospital, Dongyang, Zhejiang 322100, P.R. China.China
- 通讯作者单位
- Department of Gastrointestinal Surgery, Affiliated Nanhua Hospital, University of South China, Hengyang, Hunan 421002, P.R. China.China
- 文献类型
- 综述
- 期刊
- International journal of molecular medicine2025 Feb
- 原文标识
- PubMed 39670288 · DOI 10.3892/ijmm.2024.5468
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →